Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...
In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) ...
The complement system is an important part of the humoral immune defence in mammals that is formed by about 35 soluble and cell-surface proteins. Together these proteins enable the host to recognize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results